Skip to main content
Moderna8-K: Litigation material

Moderna and GSK settle U.S. and European patent disputes with cross-licenses

Source: Autobound Signal API · 106 signals tracked for Moderna · updated

Get Moderna's live signals in Claude or ChatGPT, or by API

AskWhat changed at Moderna this week? Use Autobound signals for modernatx.com.

What happened

Moderna entered into an agreement with GSK on October 28, 2026, settling all disputes pending in the U.S. and Europe via patent cross-licenses in infectious diseases with no license payments. This resolution removes litigation uncertainty around infectious disease programs.

Source

SEC EDGARNov 6, 2026

Current report (Form 8-K)

Moderna 8-K

Filing excerpt

Moderna and GSK entered into an agreement on October 28, 2026, to settle all disputes between the parties which were pending in the U.S. and Europe. Pursuant to the agreement, the parties granted patent cross-licenses in the field of infectious disease and are not obligated to make payments of any kind in connection with such licenses.

sec.gov/Archives/edgar/data/1682852/000168285226000194/mrna-20261106.htmRead the full source

Other signals in this filing (3)

Extracted by Autobound

From the Signal API record
Signal
8-K: Litigation material

What this signalsFilings often name leadership changes, deals and spending plans.

Form
8-K
Fiscal year end
11/06
Filed
Nov 6, 2026

More 8-K signals at other companies

The full record

From the Signal API record

Details

CIK
1682852
Accession number
0001682852-26-000194
Filing year
2026
Why it matters
Legal tech opportunity
Signal category
Risk

Topics and mentions

Regions named

  • U.S.
  • Europe

Extraction

Confidence
High
Relevance
80%
Sentiment
Positive
Detected
Nov 10, 2026
signal_type
sec-8k
signal_subtype
litigationMaterial

Use this data

Get every 8-K signal for Moderna and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Moderna this week?”

  2. Send it to your own tools

    The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/10865737-230f-4faf-bd71-a92030e68f4d returns this record as JSON. POST /v1/companies/enrich returns every signal for modernatx.com.

{
  "signal_id": "10865737-230f-4faf-bd71-a92030e68f4d",
  "signal_type": "sec-8k",
  "signal_subtype": "litigationMaterial",
  "detected_at": "2026-11-10T07:04:17.243+00:00",
  "company": {
    "name": "Moderna",
    "domain": "modernatx.com"
  },
  "data": {
    "detail": "Moderna entered into an agreement with GSK on October 28, 2026, settling all disputes pending in the U.S. and Europe via patent cross-licenses in infectious diseases with no license payments. This resolution removes litigation uncertainty around infectious disease programs.",
    "summary": "Moderna and GSK settle U.S. and European patent disputes with cross-licenses",
    "excerpts": "Moderna and GSK entered into an agreement on October 28, 2026, to settle all disputes between the parties which were pending in the U.S. and Europe. Pursuant to the agreement, the parties granted patent cross-licenses in the field of infectious disease and are not obligated to make payments of any kind in connection with such licenses.",
    "relevance": 0.8,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1682852/000168285226000194/mrna-20261106.htm",
    "filing_date": "2026-11-06",
    "filing_year": 2026,
    "fiscal_year_end": "11/06",
    "sales_relevance": "Legal tech opportunity",
    "signal_category": "risk",
    "regions_mentioned": [
      "U.S.",
      "Europe"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.